×
Before Image Before Image
After Image After Image

In a world increasingly powered by Artificial Intelligence (AI), it is difficult to separate the signal from the noise. The focus often becomes performative rather than purposeful.

Separation of the signal from the noise is important especially in life sciences, where context and precision are crucial to deliver impact. Every insight, process, and decision can influence lives.

That’s why you need nuance.

Blending our domain expertise with digital-first, AI-driven approaches, we solve some of the most complex problems of the life sciences industry.

Because at Indegene, we don’t just use AI - we apply it mindfully to maximize impact and unlock breakthroughs that truly transform patient care and outcomes.

About Indegene

Indegene Limited (BSE: 544172, NSE: INDGN) is a digital-first life sciences commercialization company, enabling biopharmaceutical, emerging biotech, and medical device companies to develop, launch, and scale the impact of their products with greater speed, precision, and efficiency.

5,000+

Employees

19

Global Offices

73

Active Clients

20/20

Top Global Biopharma Companies Served

65.5%

Revenue From Top 20 Global BiopharmaCompanies

41

Clients With US$ 1 Million+ Revenue

Key Differentiators

Strengths in an AI-Powered Era

Indegene enjoys a differentiated positioning as a digital-first commercialization and transformation partner to the life sciences industry.

Message from the Chairman and CEO

I am grateful, very deeply so, for the continuing trust of our customers and partners, who have helped us trace 25+ years of being purposeful for the life sciences industry.

Manish Gupta
Chairman and CEO Indegene

Performance Highlights

Sustaining our Growth Momentum

FY 2024-25 was another year of stable and profitable growth. We will continue to focus on strong execution, margin improvement and greater value creation for our clients in FY 2025-26 and accelerate our growth.

Suhas Prabhu
CFO, Indegene
Revenue

₹ 28,393

million

9.6%

vs FY 2023-24

EBITDA

₹ 5,622

million

5.0%

vs FY 2023-24

PAT

₹ 4,067

million

20.8%

vs FY 2023-24

Bank Balances and Current Investment

₹ 16,643

million

68.5%

vs FY 2023-24

Net Worth

₹ 26,156

million

83.0%

vs FY 2023-24

Awards and Recognition

Recognized for Innovation and Excellence

Our pursuit of innovation, people-first culture, and responsible practices has earned us recognition across multiple areas.

Everest Group Front-Runner in GenAI Life Sciences Market Adoption

Financial Times High- Growth Companies in Asia Pacific

Ecovadis Silver Medal For Sustainability And Responsible Business Practices

Deloitte Technology Fast 50 India

Stevie Awards Technical Innovation of the Year (Silver) and Technology Breakthrough of the Year (Bronze) Healthcare Technology

Business Intelligence Group Big Innovation Award

Data Breakthrough Award For Data Warehouse Solution of the Year

Analytics India Magazine (AIM) Data Engineering Company of the Year

Great Place to Work

Best Companies for Women in India - Hall of Fame - Avtar & Seramount

People Business Consulting Top 50 Companies with Great Managers in India

Analytics India Magazine (AIM) 50 Best Firms for Data Scientists to Work For